FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy

The pharmacological treatment of chronic obstructive pulmonary disease (COPD) is largely based on inhaled bronchodilators. Inspiratory flow and lung deposition are key parameters to be considered in inhaled therapy; however, the relationship between these two parameters, the patient specificities, a...

Descripción completa

Detalles Bibliográficos
Autores: González-Torralba, Fernando, Baloira, Adolfo, Abad, Araceli, Fuster Gomila, Antonia, García-Rivero, Juan Luis, García-Sidro, Patricia, Márquez-Martín, Eduardo, Palop, Marta, Soler, Nestor, Velasco, José Luis
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/18037
Acceso en línea:https://hdl.handle.net/20.500.13003/18037
Access Level:acceso abierto
Palabra clave:Lung
Dry Powder Inhalers
Equipment Design
Nebulizers and Vaporizers
Administration, Inhalation
Pulmonary Disease, Chronic Obstructive
Humans
Consensus
Bronchodilator Agents
Metered Dose Inhalers
Consenso
Enfermedad Pulmonar Obstructiva Crónica
Broncodilatadores
Humanos
Diseño de Equipo
Pulmón
Inhaladores de Dosis Medida
Administración por Inhalación
Inhaladores de Polvo Seco
Nebulizadores y Vaporizadores
id ES_77de983f7a5d861aed971d12e3e2d6d7
oai_identifier_str oai:docusalut.com:20.500.13003/18037
network_acronym_str ES
network_name_str España
repository_id_str
spelling FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled TherapyGonzález-Torralba, FernandoBaloira, AdolfoAbad, AraceliFuster Gomila, AntoniaGarcía-Rivero, Juan LuisGarcía-Sidro, PatriciaMárquez-Martín, EduardoPalop, MartaSoler, NestorVelasco, José LuisLungDry Powder InhalersEquipment DesignNebulizers and VaporizersAdministration, InhalationPulmonary Disease, Chronic ObstructiveHumansConsensusBronchodilator AgentsMetered Dose InhalersNebulizers and VaporizersConsensoEnfermedad Pulmonar Obstructiva CrónicaBroncodilatadoresHumanosDiseño de EquipoPulmónInhaladores de Dosis MedidaAdministración por InhalaciónInhaladores de Polvo SecoNebulizadores y VaporizadoresThe pharmacological treatment of chronic obstructive pulmonary disease (COPD) is largely based on inhaled bronchodilators. Inspiratory flow and lung deposition are key parameters to be considered in inhaled therapy; however, the relationship between these two parameters, the patient specificities, and the suitability of the inhaler type for COPD management has not been fully addressed. The present study follows a Delphi Panel methodology to find expert consensus on the role of inspiratory flow and lung deposition as key decision factors in COPD inhaled therapy. A two-round Delphi Panel, consisting of 38 statements (items) and completed by 57 Spanish pulmonologists, was carried out to measure the experts' consensus degree with each item. A high degree of consensus was reached on most of the items consulted, among these inspiratory flow or inspiratory capacity should be periodically considered when choosing an inhalation device and to ensure the suitability of the inhaler used; the outflow velocity and particle size of the different devices should be considered to ensure adequate lung deposition; an active device (pressurized metered-dose inhalers (pMDI) or soft mist inhalers (SMI)) should be used in patients with low inspiratory flow to achieve adequate lung deposition; and, the use of dry powder inhalers (DPI) should be re-evaluated in patients with severe obstruction and severe exacerbations. This study shows the relevance of inspiratory flow and the degree of particle deposition in the lung in the choice of an inhalation device for COPD management, as well as the convenience of an SMI type device in cases of low inspiratory flow. Moreover, it highlights the scarcity of information on the specific features of inhalation devices in COPD guidelines.Dove20222022-05-0420222022-05-04research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/18037reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/180372026-06-22T12:44:07Z
dc.title.none.fl_str_mv FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
title FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
spellingShingle FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
González-Torralba, Fernando
Lung
Dry Powder Inhalers
Equipment Design
Nebulizers and Vaporizers
Administration, Inhalation
Pulmonary Disease, Chronic Obstructive
Humans
Consensus
Bronchodilator Agents
Metered Dose Inhalers
Nebulizers and Vaporizers
Consenso
Enfermedad Pulmonar Obstructiva Crónica
Broncodilatadores
Humanos
Diseño de Equipo
Pulmón
Inhaladores de Dosis Medida
Administración por Inhalación
Inhaladores de Polvo Seco
Nebulizadores y Vaporizadores
title_short FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
title_full FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
title_fullStr FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
title_full_unstemmed FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
title_sort FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy
dc.creator.none.fl_str_mv González-Torralba, Fernando
Baloira, Adolfo
Abad, Araceli
Fuster Gomila, Antonia
García-Rivero, Juan Luis
García-Sidro, Patricia
Márquez-Martín, Eduardo
Palop, Marta
Soler, Nestor
Velasco, José Luis
author González-Torralba, Fernando
author_facet González-Torralba, Fernando
Baloira, Adolfo
Abad, Araceli
Fuster Gomila, Antonia
García-Rivero, Juan Luis
García-Sidro, Patricia
Márquez-Martín, Eduardo
Palop, Marta
Soler, Nestor
Velasco, José Luis
author_role author
author2 Baloira, Adolfo
Abad, Araceli
Fuster Gomila, Antonia
García-Rivero, Juan Luis
García-Sidro, Patricia
Márquez-Martín, Eduardo
Palop, Marta
Soler, Nestor
Velasco, José Luis
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Lung
Dry Powder Inhalers
Equipment Design
Nebulizers and Vaporizers
Administration, Inhalation
Pulmonary Disease, Chronic Obstructive
Humans
Consensus
Bronchodilator Agents
Metered Dose Inhalers
Nebulizers and Vaporizers
Consenso
Enfermedad Pulmonar Obstructiva Crónica
Broncodilatadores
Humanos
Diseño de Equipo
Pulmón
Inhaladores de Dosis Medida
Administración por Inhalación
Inhaladores de Polvo Seco
Nebulizadores y Vaporizadores
topic Lung
Dry Powder Inhalers
Equipment Design
Nebulizers and Vaporizers
Administration, Inhalation
Pulmonary Disease, Chronic Obstructive
Humans
Consensus
Bronchodilator Agents
Metered Dose Inhalers
Nebulizers and Vaporizers
Consenso
Enfermedad Pulmonar Obstructiva Crónica
Broncodilatadores
Humanos
Diseño de Equipo
Pulmón
Inhaladores de Dosis Medida
Administración por Inhalación
Inhaladores de Polvo Seco
Nebulizadores y Vaporizadores
description The pharmacological treatment of chronic obstructive pulmonary disease (COPD) is largely based on inhaled bronchodilators. Inspiratory flow and lung deposition are key parameters to be considered in inhaled therapy; however, the relationship between these two parameters, the patient specificities, and the suitability of the inhaler type for COPD management has not been fully addressed. The present study follows a Delphi Panel methodology to find expert consensus on the role of inspiratory flow and lung deposition as key decision factors in COPD inhaled therapy. A two-round Delphi Panel, consisting of 38 statements (items) and completed by 57 Spanish pulmonologists, was carried out to measure the experts' consensus degree with each item. A high degree of consensus was reached on most of the items consulted, among these inspiratory flow or inspiratory capacity should be periodically considered when choosing an inhalation device and to ensure the suitability of the inhaler used; the outflow velocity and particle size of the different devices should be considered to ensure adequate lung deposition; an active device (pressurized metered-dose inhalers (pMDI) or soft mist inhalers (SMI)) should be used in patients with low inspiratory flow to achieve adequate lung deposition; and, the use of dry powder inhalers (DPI) should be re-evaluated in patients with severe obstruction and severe exacerbations. This study shows the relevance of inspiratory flow and the degree of particle deposition in the lung in the choice of an inhalation device for COPD management, as well as the convenience of an SMI type device in cases of low inspiratory flow. Moreover, it highlights the scarcity of information on the specific features of inhalation devices in COPD guidelines.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-05-04
2022
2022-05-04
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/18037
url https://hdl.handle.net/20.500.13003/18037
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial 4.0 Internacional
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial 4.0 Internacional
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Dove
publisher.none.fl_str_mv Dove
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411153892868096
score 15.812429

Similares en LA Referencia